Specify a stock or a cryptocurrency in the search bar to get a summary
EXACT Sciences Corporation
EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Address: 5505 Endeavor Lane, Madison, WI, United States, 53719
Analytics
WallStreet Target Price
92.69 USDP/E ratio
–Dividend Yield
2.09 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EXAS
Dividend Analytics EXAS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EXAS
Stock Valuation EXAS
Financials EXAS
Results | 2019 | Dynamics |